Androgen Receptor
Androgen receptor (AR) is a type of nuclear receptor that is activated by binding of either of the androgenic hormones testosterone or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. The androgen receptor is most closely related to the progesterone receptor, and progestins in higher dosages can block the androgen receptor. The main function of the androgen receptor is as a DNA-binding transcription factor that regulates gene expression. Androgen regulated genes are critical for the development and maintenance of the male sexual phenotype. Mutations in this gene are also associated with complete androgen insensitivity (CAIS).
All Product Categories
-
Androgen Receptor Inhibitors
(128)
View all products
-
Androgen Receptor Agonists
(27)
View all products
-
Androgen Receptor Antagonists
(150)
View all products
-
Androgen Receptor Activators
(3)
View all products
-
Androgen Receptor Modulators
(39)
View all products
-
Androgen Receptor Inducer
(1)
View all products
-
Androgen Receptor Degraders
(53)
View all products
-
Androgen Receptor Controls
(3)
View all products
-
Androgen Receptor Ligands
(26)
View all products
-
Androgen Receptor Proteins
(1)
View all products
-
Androgen Receptor Related Products (486)
Related Products (486)
-
Recombinant Proteins (1)
-
Antibodies (2)
-
Acetyl-ACTH (3-24) (human, bovine, rat)
0 ImagesCat. No.: HY-P4782CAS No.: 1815617-99-2Acetyl-ACTH (3-24) (human, bovine, rat) is a fragment of proopiomelanocortin (POMC) peptide. POMC peptides such as adrenocorticotrophin (ACTH), which is the precursor of α-MSH, is also an agonist at the MC-1 receptor.
-
MK-3984
0 ImagesCat. No.: HY-111246CAS No.: 871325-55-2MK-3984 is a selective androgen receptor modulator (SARM). MK-3984 can be used for the research of muscle wasting associated with cancer.
-
AR antagonist 10
0 ImagesCat. No.: HY-170951CAS No.: 3068489-78-8AR antagonist 10 (Compound Y5) is potent and orally active androgen receptor (AR) antagonist with an IC50 of 0.04 μM. AR antagonist 10 demonstrates dual mechanisms of action, antagonizes AR by disrupting AR dimerization, and induces AR degradation via the ubiquitin-proteasome pathway. AR antagonist 10 exhibits excellent activity against variant drug-resistant AR mutants. AR antagonist 10 effectively suppresses the tumor growth of the LNCaP xenograft. AR antagonist 10 is potential to be used for drug-resistant prostate cancer.
-
AR antagonist 9
0 ImagesCat. No.: HY-159922AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC50 value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC50 = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against ARF876L/T877A and ARW741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance.
-
AR antagonist 12
0 ImagesCat. No.: HY-173559CAS No.: 2902679-42-7AR antagonist 12 (compound 20i) is an orally active androgen receptor antagonist wiith IC50 values of 119.3 μM and 98.2 μM for wt-AR and AR-F877L,respectively. AR antagonist 12 induces a dose-dependent and time-dependent reduction in AR, AR-V7, and PSA protein levels. AR antagonist 1 shows anticancer activuty and can be used for the study of Enzalutamide (HY-70002)-resistant Prostate cancer.
-
LYA914
0 ImagesCat. No.: HY-175455LYA914 is an orally effective AR/AR-V7 PROTAC degrader. LYA914 recruits CRBN to target and bind the conserved DBD domain of AR and AR-V7, inducing their ubiquitination and subsequent degradation, thereby completely blocking AR signaling and transcriptional activity. LYA914 can be used for the research of castration-resistant prostate cancer.
-
Androgen receptor antagonist 4
0 ImagesCat. No.: HY-146027CAS No.: 354815-43-3Androgen receptor antagonist 4 (Compound AT2) is an androgen receptor (AR) antagonist with an IC50 of 0.15 μM. Androgen receptor antagonist 4 efficiently antagonizes AR transcriptional activity, suppresses downstream target gene of AR, and blocks the DHT-induced AR nuclear translocation. Androgen receptor antagonist 4 shows anticancer activities.
-
(+)-JNJ-37654032
0 ImagesCat. No.: HY-111044CAS No.: 944919-15-7(+)-JNJ-37654032 is an orally active and selective androgen receptor modulator. (+)-JNJ-37654032 can be used in the study of muscle-wasting diseases.
-
AR antagonist 6
0 ImagesCat. No.: HY-160680CAS No.: 876760-08-6AR antagonist 6 (compound 6i) is a diphenyl ether androgen receptor (AR) antagonist that binds AR at a concentration of 120 nM. AR antagonist 6 exhibits low toxicity and in vitro activity against the golden Syrian hamster ear model.
-
RLA-4842
0 ImagesCat. No.: HY-152512RLA-4842 is an iron activator containing anti-androgen. RLA-4842 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line.
-
Androgen receptor-IN-4
0 ImagesCat. No.: HY-151220CAS No.: 2759137-87-4Androgen receptor-IN-4 (Compound 206) is an androgen receptor inhibitor, and can be used for research of Kennedy's disease.
-
Medroxyprogesterone acetate-d7
0 ImagesCat. No.: HY-B0469S1Synonyms: Medroxyprogesterone 17-acetate-d7; Farlutin-d7Medroxyprogesterone acetate-d7 (Medroxyprogesterone 17-acetate-d7) is the deuterium labeled Medroxyprogesterone acetate (HY-B0469) . Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors.
-
HG122
0 ImagesCat. No.: HY-143535CAS No.: 1854976-77-4HG122 promotes androgen receptor (AR) degradation through the proteasome pathway inhibiting the castration-resistant prostate cancer.
-
AR antagonist 2
0 ImagesCat. No.: HY-142923CAS No.: 2275752-15-1AR antagonist 2 (compound 58) is a potent androgen receptor (AR) inhibitor with an IC50 of 0.95 μM. AR antagonist 2 has the potential for cancer research.
-
Androgen receptor antagonist 12
0 ImagesAndrogen receptor antagonist 12 (Compound EF2) is an orally active Androgen receptor (AR) antagonist (IC50: 0.30 μM). Androgen receptor antagonist 12 inhibits transcriptional activity of variant AR mutants and and the proliferation of AR-positive PCa cell lines. Androgen receptor antagonist 12 blocks AR nuclear translocation. Androgen receptor antagonist 12 inhibits tumor growth in a C4-2B xenograft mouse model. Androgen receptor antagonist 12 can be used for prostate cancer (PCa) research.
-
Ludaterone
0 ImagesCat. No.: HY-137444CAS No.: 124548-08-9Ludaterone is an antiandrogen agent, with potent antiandrogenic activity.
-
7-Methoxy-4H-chromen-4-one-o-carborane
0 ImagesCat. No.: HY-183188CAS No.: 3097646-97-1
-
Androgen receptor ligand 4
0 ImagesCat. No.: HY-123579CAS No.: 92071-89-1Androgen receptor ligand 4 (Compound MDG486) is an androgen receptor ligand with an IC50 of >100 µM. Androgen receptor ligand 4 can be used in the research of adolescent development.
-
Adrenosterone-13C3
0 ImagesCat. No.: HY-W759219Synonyms: (+)-Adrenosterone-13C3; 11-Keto-androstedione-13C3Adrenosterone-13C3 ((+)-Adrenosterone-13C3) is the 13C-labeled Adrenosterone (HY-17462). Adrenosterone ((+)-Adrenosterone) is a competitive hydroxysteroid (11-beta) dehydrogenase 1 (HSD11β1) inhibitor. Adrenosterone is a steroid hormone with weak androgenic effect. Adrenosterone is a dietary supplement that can decrease fat and increase muscle mass. Adrenosterone acts as a suppressor of metastatic progression of human cancer cells.
-
SRC2-2 peptide
0 ImagesCat. No.: HY-P11443CAS No.: 245122-99-0SRC2-2 peptide is a a coactivator-derived mimic targeting androgen receptor (AR) ligand. SRC2-2 peptide is promising for research of prostate cancer.
